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Background: Eurycoma longifolia (EL) has been shown recently to protect against bone calcium loss in
orchidectomised rats, the model for androgen-deficient osteoporosis. The mechanism behind this is unclear but it
may be related to its ability to elevate testosterone levels or it may directly affect bone remodeling. The aim of this
study is to determine the mechanism involved by investigating the effects of EL extract on serum testosterone
levels, bone biomarkers, biomechanical strength and gene expression of Receptor Activator of Nuclear Factor
kappa-B ligand (RANKL), Osteoprotegerin (OPG) and Macrophage-Colony Stimulating Factor (MCSF) in
orchidectomised rats.
Methods: Thirty-two male Sprague–Dawley rats were divided into: Sham-operated group (SHAM);
orchidectomised-control group (ORX); orchidectomised and given 15 mg/kg EL extract (ORX + EL) and
orchidectomised and given 8 mg/kg testosterone (ORX + T). The rats were treated for 6 weeks. The serum levels of
testosterone, osteocalcin and C-terminal telopeptide of type I collagen (CTX) were measured using the ELISA
technique. The femoral bones were subjected to biomechanical testing. The tibial bone gene expressions of RANKL,
OPG and MCSF were measured using the branch DNA technique.
Results: The post-treatment level of testosterone was found to be significantly reduced by orchiectomy (p < 0.05).
Both ORX + EL and ORX + T groups have significantly higher post-treatment testosterone levels compared to their
pre-treatment levels (p < 0.05). The bone resorption marker (CTx) was elevated after orchiectomy but was
suppressed after treatment in the ORX + EL and ORX + T groups (p < 0.05). There was no significant finding for the
femoral biomechanical parameters. The tibial OPG gene expression in the ORX group was significantly lower
compared to the SHAM and ORX + EL groups (p < 0.05).
Conclusion: Supplementation with EL extract elevated the testosterone levels, reduced the bone resorption marker
and upregulated OPG gene expression of the orchidectomised rats. These actions may be responsible for the
protective effects of EL extract against bone resorption due to androgen deficiency.
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Osteoporosis in men is gaining more interests as it is be-
coming one of the main cause of morbidity and mortal-
ity in older men. Approximately 2 million men in the
United States suffered from osteoporosis [1] and 1.5 mil-
lion of them are more than 65 years old [2]. Osteopor-
osis is usually asymptomatic and commonly presents
with fractures due to minimal trauma [3]. The mortality
associated with hip fractures is higher in men than in
women and men are twice likely to die following a hip
fracture (14% versus 6% for women) [4]. It is estimated
that 31% of men with hip fracture died within 1 year
after fracture as compared to only 17% of women [5].
There are very few studies carried out on osteoporosis in
males but the necessity for potential therapeutic options
is increasing due to an increase in male life expectancy
and the associated hypogonadism.
The main cause of osteoporosis in men is androgen
deficiency due to natural aging [6]. Partial androgen de-
ficiency is common in aged men as 20–30% of them suf-
fered from testosterone deficiency, exposing them to a
high rate of bone loss which may lead to osteoporosis
[7]. The testosterone- deficient state was shown to pro-
mote bone resorption only, as the CTx levels were found
to be elevated in orchidectomised rats but the osteocal-
cin remained unchanged. Furthermore, testosterone re-
placement prevented the CTx elevation induced by
orchiectomy [8]. Human studies have shown that testos-
terone replacement therapy caused a reductions in bone
resorptive markers [9-11] and increased calcium absorp-
tion and bone formation [12].
The most widely practiced means of testosterone ther-
apy is by intramuscular injection. It provides immediate
testosterone surge but is painful and associated with
prostate cancer and liver dysfunction. The oral form of
testosterone is largely converted into inactive metabo-
lites by the liver and is associated with liver tumors.
Transdermal testosterone in the form of cream and gel
may be sticky and has a bad odour. There are also con-
cerns regarding transference of the applied testosterone
cream or gel to women and children by skin contact.
This is also the most expensive form of testosterone as
the concentration required may be up to 4 to 5 times
higher than other preparations [13]. With all these pro-
blems with testosterone therapy, alternative treatment
modalities that have testosterone-like action are required
for treatment of testosterone deficiency and preventing
the associated bone loss.
Eurycoma longifolia (EL), classified under the Simar-
oubaceae family, is a tall and slow growing tree found in
South-east Asian countries. The plant extract is widely
used to enhance male sexuality in Asia. The active ingre-
dients are called quassinoids and are found in the root
[14]. Studies have confirmed its aphrodisiac andergogenic effects [15-19]. Our previous study found that
supplementation of EL to orchidectomised rats was able
to maintain the bone calcium content. EL may have
achieved this by modulating the bone resorptive activity
of osteoclasts [8].
Many factors that affect bone resorption were found
to do so by altering Receptor Activator of Nuclear Fac-
tor kappa-B ligand (RANKL) and Osteoprotegerin
(OPG) production [20]. RANKL is a very important
cytokine for differentiation and activation of osteoclasts
[21]. It was reported that the administration of serum
RANKL to mice promoted osteoclast growth and acti-
vation, leading to osteoporosis [22]. Furthermore, a
human study by Stern et al., [23], found that high
RANKL levels were associated with low bone mineral
density (BMD) in men but no RANKL-BMD associa-
tions were found in women. They proposed that the in-
verse RANKL-BMD association in men may be related
to testosterone levels.
The antiresorptive decoy receptor (OPG) opposes
RANKL by binding with RANKL and preventing RANKL
from binding to RANK receptors. As a result, OPG inhi-
bits the osteoclastogenetic process and bone resorption.
Osteoclastogenesis also requires Macrophage-Colony
Stimulating Factor (MCSF), which is also expressed by
osteoblasts. MCSF, binds to the MCSF receptors situated
in the osteoclasts, but the mechanism to modulate osteo-
clastogenesis is still not clear [24].
To the best of our knowledge, there is no study on the
mechanism of EL extract in preventing bone loss due to
androgen deficiency. Originally, EL extract was used by
men for its aphrodisiac effects, believed to be contribu-
ted by its ability to raise testosterone levels. A study has
shown that EL extract was capable of enhancing testos-
terone production [25]. In order to confirm that the
testosterone-raising ability of EL extract may be respon-
sible for its effects on bone, the serum testosterone
levels were measured in our rat model. The bone resorp-
tive marker, CTX and bone formation marker, osteocal-
cin were measured to determine its effect on bone
remodeling. The biomechanical strength of the bones
was also assessed. As the differentiation and activation
of osteoclast are influenced by the RANKL/OPG system
and MCSF, their gene expressions were measured to de-
termine the molecular mechanism of EL extract in pro-
tecting bone against androgen-deficient osteoporosis.
Methods
Animal model
Thirty two male Sprague Dawley rats, aged 10 months
old and weighing between 250 to 300 grams were
used. The study had been approved by the UKM Ani-
mal Ethics Committee (FP/FAR/2008/NAZRUN/13-
FEB/217-FEB-2008-FEB-2010). The rats were divided
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orchidectomised-control (ORX), orchidectomised and
given testosterone replacement (ORX + T) and orchi-
dectomised and supplemented with EL (ORX + EL).
Middle-aged orchidectomised rats were used as the
model for androgen-deficient osteoporosis [26]. Before
performing orchiectomy, the rats were anesthetized with
Ketapex:Xylazil (1:1). A 2-cm ventral midline incision
was made in the scrotum and the tunica was pierced.
The testes were pushed out and raised to expose the
underlying blood vessels and tubules. The spermatic
chord was clamped and tied with absorbable catgut su-
ture at the confluence of the blood vessels and epididy-
mis. The testes were removed and all deferential vessels
and ducts were replaced back into the tunica. The tunica
of the contralateral side was similarly penetrated and the
procedure repeated. The scrotal incision was closed back
with a suture.
Eurycoma longifolia extract
Eurycoma longifolia Jack extract was obtained from
Phytes Biotek Sdn. Bhd. (Selangor, Malaysia), a licensed
GMP manufacturer of herbal products, in the form of
a freeze-dried standardized extract (Batch No: TA
071210). It was extracted using a patented high pres-
sure water extraction process (US 7,132,117 B2), fil-
tered at 1–4 micron and freeze dried without
maltodextrin or lactose. Physically, it was a light brown
fine powder with 4-6% moisture content. Its major
chemical components were proteins (31.75%), glycosa-
ponins (41.08%) and eurycomanone (1.604%). This ex-
tract was the same form used for human consumption
as health supplements [27].
The EL aqueous extract powder was dissolved in nor-
mal saline and given via oral gavage at the doses of
15 mg/kg rat weight daily at 9 am for 6 weeks [25].
Testosterone was purchased from TCI UK Ltd (UK). It
was diluted in olive oil (Bertolli, Italy) and 8 mg/kg
was injected intramuscularly once daily at 9 am for
6 weeks [28].
Body weights were measured weekly. Blood samples
were collected twice; before the start of treatment and
after 6 weeks of treatment. They were obtained under
anesthesia from the retro-orbital vein. The blood was
then centrifuged at 2000 xg for 10 minutes and the
serum stored at −70°C. At the end of treatment, the rats
were euthanized and both tibiae and femora were
removed, cleansed of all soft tissues and stored at −70°C.
Bone biochemical markers
Bone biochemical markers of serum osteocalcin and C-
terminal telopeptide of type I collagen (CTX) were mea-
sured using an ELISA reader (VERSAmax, Sunnyvale,
USA). The kits used were the Rat Osteocalcin ELISA(Biomedical Technologies, Herlev, Denmark) and
RatlapsTM ELISA CTX-1 kits (Nordic Biosciences, IDS
UK). The testosterone levels were also measured using
the Testosterone ELISA Kit ( i-DNA Biotechnology,
Hamburg, Germany).
Biomechanical testing
The femora were prepared for biomechanical testing.
They were kept moist at all time by wrapping them with
gauze soaked in phosphate buffered solution and
aluminum foil. The study groups were numbered to
blind the operators. Each femur was placed on the
Instron machine (Instron Microtester 5848, Instron
Corp., USA) in a three-point bending configuration. The
load was applied at the mid-diaphysis in an anteropos-
terior direction with a loading speed of 5 mm/min until
the femur fractured. The load, stress and strain-
deflection curves were automatically calculated by the
computer using the Bluehill software.
Gene expression
The tibial bones were grounded into a fine powder
with mortar and pestle with addition of liquid nitro-
gen. Proteinase K was added to release the ribonucleic
acid (RNA) and prepared according to directions sug-
gested by Panomics (Fremont, CA) for analysis of
mRNA expression using the Panomics QuantiGene
Plex 2.0 system. The method combines RNA signal
amplification and microspheres with unique fluorescent
signatures to enable quantitation of multiple mRNA
targets simultaneously in the same sample, without
having the amplification inaccuracies of RT-PCR, and
allows for discrimination of highly homologous mes-
sages [29,30]. Specific oligonucleotide capture and ex-
tender probe sets (3 per target), designed to anneal
exclusively to each mRNA of interest and each house-
keeping mRNA, were designed by Panomics to unique
sequences within each message sequence. Probe sets
were located in the following regions of each mRNA
species: RANKL (NM_057149), OPG (NM_012870),
M-CSF (NM_023981). Housekeeping genes were:
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
NM_017008), Glucuronidase,, beta (NM_017015) and
hypoxanthine phosphoribosyltransferase 1 (HPRT1;
NM_012583). Specific mRNA transcripts were captured
to specific fluorescent beads by hybridization to cap-
ture probe-extender probe interactions. The signal
from each hybridized unit was amplified by attachment
of biotinylated label probes at multiple binding sites
on the complexes, which in turn bound to
streptavidin-conjugated R-phycoerythrin (SAPE) to pro-
duce fluorescence. The fluorescent signals associated
with individual capture beads were read using a Lumi-
nex 100 IS system (Luminex Corp., Austin, TX, US)
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the SAPE signal designating abundance. For each well,
the total fluorescence from each individual bead type
(corresponding to individual mRNA species) minus
background fluorescence for that bead type was nor-
malized to the geometric mean of the fluorescence of
the 3 housekeeping genes also in that well. The nor-
malized signals for individual mRNAs from triplicate
wells were averaged to yield a single value for each
mRNA species being measured.
Statistical analysis
For normally distributed data, the statistical test used
was ANOVA followed by Tukey’s hsd. Data that was not
normally distributed data was analyzed using Mann–
Whitney followed by Kruskal-Wallis test if more than
two groups were compared. The level of significance
was taken as p <0.05
Results
Body weight
There was a significant weight gain at the end of the
treatment period for all the groups except for the ORXC
group. Following 6 weeks of treatment, the final body-
weight of the ORXC group was significantly lower than
the rest of the groups (Figure 1).
Testosterone level
Before treatment, there was no significant difference in
the testosterone levels between the groups. After 6 weeks
of treatment, the serum testosterone level of the ORXCFigure 1 Mean rat weight before and after treatment. Data were prese
significant difference before and after treatment. Same alphabet indicate si
Sham- operated group. ORX : Orchidectomized control group. ORX + T : O
Orchidetctomized group treated with EL.group was significantly lower than its pre-treatment
level. Orchidectomised rats receiving testosterone re-
placement (ORX + T) or EL supplementation (ORX +
EL) had significantly higher post-treatment levels of tes-
tosterone compared to their respective pre-treatment
levels. When the post-treatment testosterone levels of
the different groups were compared, the ORX + T group
had significant higher level than the SHAM and ORXC
groups but not significantly different compared to the
ORX + EL (Figure 2).
Bone biochemical markers
The post-treatment level of CTx for the ORXC group
was significantly elevated compared to its pre-treatment
level. In contrast, there was significant reduction in the
post-treatment levels of CTx for the ORX + EL and
ORX + T groups compared to their respective pre-
treatment levels (Figure 3A). There were no significant
changes in the osteocalcin levels for all the groups
(Figure 3B).
Biomechanical test
There were no significant differences in all the biomech-
anical parameters for all the groups, even though the
Young modulus appeared to be reduced by orchiectomy
and revived by testosterone or EL supplementation
(Figures 4A–D).
Gene expression
The RANKL gene expression of the tibial bones for all
the groups was not significantly different from eachnted as mean ± SEM with significant difference p < 0.05. *indicate
gnificant difference between the groups after treatment. SHAM :
rchidectomized group treated by testosterone. ORX + EL :
Figure 2 The testosterone levels before and after treatment. Data were presented as mean ± SEM with significant difference p < 0.05.
*indicate significant difference before and after treatment. Same alphabet indicate significant difference between the groups after treatment.
SHAM : Sham- operated group. ORX : Orchidectomized control group. ORX + T : Orchidectomized group treated by testosterone. ORX + EL :
Orchidetctomized group treated with EL.
Figure 3 A and B The serum C-terminal telopeptide of type 1 collagen (CTX) and osteocalcin levels before and after treatment for all
the groups. Data were presented as mean ± SEM with significant difference p < 0.05. *indicate significant difference before and after treatment.
SHAM : Sham- operated group. ORX : Orchidectomized control group. ORX + T : Orchidectomized group treated by testosterone. ORX + EL :
Orchidetctomized group treated with EL.
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Figure 4 A, B, C and D: The Load, Stress, Strain and Young Modulus for all the groups. Data were presented as mean ± SEM with
significant difference p < 0.05. SHAM : Sham- operated group. ORX : Orchidectomized control group. ORX + T : Orchidectomized group treated
by testosterone. ORX + EL : Orchidetctomized group treated with EL.
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bone was decreased after orchiectomy as shown by the
significant drop in the OPG gene expression of ORX
compared to SHAM groups. EL supplementation (ORX +
EL) was able to increase the OPG gene expression back to
SHAM level. Testosterone therapy (ORX + T) did not
cause any significant difference in the OPG gene expression
compared to the other groups (Figure 5B). The MCSF gene
expression of the rat femur seemed to be increased after
orchiectomy (ORX) and reduced with EL supplementation
(ORX + EL) and testosterone therapy (ORX + T). However,
the difference were not significant (Figure 5C).
Discussion
The orchidectomised rats in our study failed to gain
weight normally until its body weight was significantly
lower than the rest of the groups. Testosterone reduc-
tion due to orchiectomy may have caused the weight
loss due to loss of muscle and bone mass [31]. Testoster-
one and EL extract were able to prevent these reductions
and therefore maintained the weight gain of the orchi-
dectomized rats.
Orchidectomized rat is an accepted model for studying
the skeletal effects of androgen deficiency in hypo-
gonadal men [26]. As expected, the testosterone levels of
the orchidectomised rats in our study were significantlyreduced while testosterone therapy significantly raised
the testosterone levels. Similar results were obtained by
other studies whereby orchiectomy had caused 80% re-
duction in serum testosterone in male rats [32], while
testosterone replacement was able to raise the testoster-
one levels [33]. Interestingly, EL extract supplementation
to orchidectomized rats at 15 mg/kg for 6 weeks was
able to elevate the serum testosterone level significantly.
The only published report on the effects of EL on testos-
terone levels was by Zanoli et al. [34]. They found that
supplementation of EL extract to adult male Sprague–
Dawley rats at 500 mg/kg for 6 days had significantly
raised the testosterone levels compared to unsupplemen-
ted rats. The dose given to the intact rats by Zanoli et al.
[34] was very much higher than ours, but the duration
of treatment was shorter. A daily dose level of 270–
350 mg/kg was found to be rather safe without any
effects on the liver, kidneys, spleen, and testes [35].
The question now is how EL extract was able to raise
the testosterone levels in the absence of the testes in our
study. In rats, there are other extra testicular sites that
synthesize androstenedione and testosterone such as the
liver, kidneys and gastro-duodenal tract [36] but not the
adrenal glands [37]. Besides that, there was significant
formation of 20α-dihydropregnenolone, the precursor of
testosterone, in all rat tissues. The enzymes involved in
Figure 5 A, B and C: The RANKL, OPG, M-CSF gene expressions for all the groups. Samples were normalized to GAPD MFI (Median
Fluorescence Intensity). Error bars represented the standard deviations of the average responses. Significant difference was taken at p < 0.05.
SHAM : Sham- operated group. ORX : Orchidectomized control group. ORX + T : Orchidectomized group treated by testosterone. ORX + EL :
Orchidetctomized group treated with EL.
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hydrogenase, 17β and 20α-hydroxysteroid dehydro-
genases were also expressed extra-glandularly in rats
[36]. In humans, serum testosterone was detected above
the sensitivity threshold even in patients who had under-
gone surgical bilateral orchiectomy. There is possibilitythat testosterone production is upregulated in those
organs other than testis in surgically castrated patients
with detectable serum testosterone measurement [38].
All these findings indicated that there will still be tes-
tosterone production even in the absence of testes.
There is a possibility that EL extract was able to
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tion in orchidectomised rats. More importantly, the
testosterone-raising ability of EL extract may be respon-
sible for its bone protective effects in orchidectomised
rats.
Testosterone levels may vary between subjects and
individuals. This was seen in mice of the same age and
strain housed under identical conditions with the testos-
terone levels ranging from 1 ng/ml to 30 ng/ml. A two
to five fold differences in plasma testosterone levels were
recorded between samples collected from the same ani-
mal at different times [39]. The wide variation in testos-
terone levels was also seen in human males, ranging
between 250 to 850 ng/dl [31]. The testosterone levels
fluctuate throughout the day as it peaks in the morning
and then gradually dropping throughout the day. We
have attempted to reduce these variations by taking the
blood samples at the same time at 9.00 am in the morn-
ing, when the testosterone levels were high. The testos-
terone levels also deteriorated with aging whereby its
level dropped to half in a 60-year-old man compared to
a young man [40].
Major changes in bone mass and micro-architecture
can be observed four weeks post-orchiectomy and these
alterations become more obvious after four months [41].
The duration of treatment in our study was six weeks as
in previous study by Shuid et al. [8]. It should be suffi-
cient for orchiectomy to produce significant bone
changes. This was reflected by an elevated CTx level
after orchiectomy, indicating increased rate of bone re-
sorption. The elevation of CTx level was suppressed by
EL extract supplementation and testosterone therapy.
Therefore, both EL supplementations and testosterone
therapy were able to prevent the increased bone resorp-
tion rate seen after orchiectomy. The results not only
confirmed the findings by others that testosterone
reduced bone resorption markers [9-11], but also con-
firmed an earlier study by Shuid et al. [8] that EL extract
was capable of doing the same.
The bone resorptive changes were not accompanied
by any significant changes in the biomechanical para-
meters. Previous studies have also failed to detect any
significant change in the bone biomechanical properties
of orchidectomised rats [42,43]. The bone strength is
determined by the bone mass and the intrinsic proper-
ties of the bone material [44,45]. It is likely that there
was no significant mechanical change in the
organization of the bone matrix of the orchidectomised
rat that may compromise the bone strength.
Since the bone marker changes in this study and an-
other previous study by Shuid et al., [8] were indicative
that orchiectomy only affected the bone resorptive activ-
ity of osteoclast, we have studied the gene expressions of
OPG, RANKL and MCSF. These factors play animportant role in the osteoclast recruitment and activa-
tion. We found significant results only for the gene ex-
pression of OPG. Orchidectomy had down-regulated the
OPG gene expression, which was elevated back to sham
level with EL extract supplementation. However, testos-
terone therapy failed to emulate EL’s action. This sug-
gested a novel regulation of OPG by EL, which may help
us to understand the mechanism in protection against
androgen-deficient bone loss. There were in vitro studies
with mixed results on the effects of testosterone on
OPG expression. Chen et al. [46] found that testosterone
was able to amplify the OPG mRNA expression in a
mouse bone-cell culture and in an osteoblastic cell line.
In contrast, Hofbauer and Heufelder [47] demonstrated
that androgens inhibited OPG production by mature
osteoblast, marrow stromal cells and murine marrow
stroma.
When the RANKL gene expression was measured in
this study, there was no significant difference in the gene
expression for all the groups. Proell et al., [48] found
that the RANKL expression was increased in the bone
marrow of orchidectomised rats, while testosterone was
able to return the RANKL gene expression to sham con-
trol levels. However two other in vitro studies did not
find any association between RANKL and orchiectomy.
Hofbauer and Heufelder [47] reported that the RANKL
mRNA was not consistently detected in mature osteo-
blasts and marrow stromal cells and it was not regulated
by androgens. Chen et al. [46] found that testosterone
did not affect RANKL mRNA expression in MC3T3-E1
or mouse bone cells.
We did not find any significant change in the M-CSF
gene expression after orchiectomy. There were also no
significant differences in the M-CSF gene expression be-
tween all the groups. In vitro study on human endomet-
rial stromal cells found that M-CSF production was
dose-dependently enhanced by the addition of testoster-
one [49].
The present study has pointed out the potential of EL
for treatment of male osteoporosis. Theoretically, the
prevalence of male osteoporosis should be lower in
South East Asian countries where EL is traditionally
used as remedy for male wellbeing. There is no credible
statistic on the incidence of male osteoporosis in Asian
countries that used EL like Malaysia and Indonesia. By
comparing the hip fracture incidence in men, the inci-
dence is 88 and 114 per 100 000 in Malaysia and Thai-
land respectively [50]. The incidence is 362 and 311 per
100 000 in Norway and Denmark respectively [51].
Therefore the incidence is much lower in countries that
used EL. However, the correlation with EL use is difficult
to determine as the percentage of men taking EL is not
known. Assuming that a significant number of men were
taking EL in South East Asia compared to Scandinavia,
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men in South East Asia was only one fourth to one third
compared to Scandinavia.
Conclusions
It can be concluded that both EL extract and testoster-
one are effective in elevating the testosterone levels,
which may explain the bone-protective effects of EL.
However, since only EL extract has affected OPG expres-
sion, this may be an additional mechanism of EL in pro-
tecting against bone resorption induced by androgen-
deficient. Further studies on the regulation of OPG pro-
duction by EL may provide insight into this novel
mechanism.
Competing interests
The author(s) declare that they have no competing interests.
Authors’ contributions
ANS and INS designed the study. EA, NME and HSAR carried out the study
and collected the samples. NM and NM participated in the statistical analysis.
All authors read and approved the final manuscript.
Acknowledgement
We are grateful to Encik Arizi and the staff of the Pharmacology Department,
UKM Medical Centre for their technical support. We thank the University
Kebangsaan Malaysia for providing the grant GUP-SK-07-21-202 for this
study.
Author details
1Department of Pharmacology, Faculty of Medicine, National University of
Malaysia (Universiti Kebangsaan Malaysia), Jalan Raja Muda Abd Aziz 50300,
KL, Malaysia. 2Department of Biomedical Science, Faculty of Health Sciences,
National University of Malaysia (Universiti Kebangsaan Malaysia), Jalan Raja
Muda Abd Aziz 50300, KL, Malaysia.
Received: 13 February 2012 Accepted: 31 August 2012
Published: 12 September 2012
References
1. Kamel HK: Male osteoporosis: new trends in diagnosis and therapy. Drugs
Aging 2005, 22:741–748.
2. Siddiqui NA, Shetty KR, Duthei EH: Osteoporosis in older men: discovering
when and how to treat it. Geriatrics 1999, 54:20–22.
3. Barham K, Chernoff A, Anantasopoulou C: Osteoporosis in men. Hosp
Physician 2007, 33:17–21.
4. Diamond TH, Thornley SW, Sekel R, Smerdely P: Hip fracture in elderly
men: prognostic factors and outcomes. Med J 1997, 167(8):412–415.
5. Forsen L, Sogaard AJ, Meyer HE: Survival after hip fracture: short and long
term excess mortality according to age and gender. Osteoporos Int 1999,
10:73–78.
6. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL,
Calvo MS, Harris TB, Heyse SP: Prevalence of low femoral bone density in
older U.S. adults from NHANES III. JBMR 1997, 12:1761–1768.
7. Kaufman JM, Vermenlen A: The decline of androgen levels in elderly men
and its clinical and therapeutic implications. Endocr Rev 2005,
26(6):833–876.
8. Shuid AN, Tajul AS, Firdaus AB, Norliza M, Norazlina M, Ima Nirwana S: The
Anti-Osteoporotic Effect of Eurycoma Longifolia in Aged
Orchidectomised Rat Model. Aging Male 2010, 14(3):150–154.
9. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A,
Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL: Effect of
testosterone treatment on bone mineral density in men over 65 years of
age. J Clin Med Endocrinol 1999, 84:1966–1972.
10. Kenny AM, Prestwood KM, Marcello KM, Raisz LG: Determinants of bone
density in healthy older men with low testosterone levels. J Gerontol Med
Sci A 2000, 55:1–6.11. Kenny AM, Prestwood KM, Gruman CA: Effects of transdermal testosterone
on bone and muscle in older men with low bioavailable testosterone
levels. J Gerontol A 2001, 56:266–272.
12. Scopacasa F, Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BE: Bone
density and bone related biochemical variables in normal men: A
longtitudinal study. Journal Geroniology 2002, 6(57):M385–M391.
13. Surampudi PN, Wang C, Swerdloff R: Hypogonadism in the aging male
diagnosis, potenytial benefits and risks of testosterone replacement
therapy. Int J Endocrinol 2012, 625434. doi:10.1155/2012/625434.
14. Chan KL, Choo CY, Morita H, Itokawa H: High performance liquid
chromatography in phytochemical analysis of Eurycoma longifolia.
Planta Med 1998, 64(8):741–745.
15. Ang HH, Sim MK: Effect of Eurycoma Longifolia Jack on sexual behavior
of male rats. Arch Pharmacol Res 1997, 20:656–658.
16. Choudhary MI, Rahman AU: Elixirs of love. Chem Br 1997, 25–27.
17. Ang HH, Cheang HS: Effects of Eurycoma longifolia Jack on laevator ani
muscle in both uncastrated and testosterone-stimulated castrated intact
male rats. Arch Pharm Res 2001, 24(5):437–440.
18. Ang HH, Ngai TH: Aphrodisiac evaluation in non-copulator male rats after
chronic administration of Eurycoma longifolia Jack: Fundam. Clin
Pharmacol 2001, 15(4):265–268.
19. Hamzah S, Yusof A: The ergogenic effects of Eurycoma longifolia Jack: A
pilot Study. Br J Sports Med 2003, 37(5):465.
20. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000,
289:1504–1508.
21. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R,
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E,
Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo
J, Delaney J, Boyle WJ: Osteoprotogerin ligand is a cytokine that
regulated osteocast differentiation and activation. Cell 1998, 93:165–176.
22. Lloyd SAJ, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S, Stolina M,
Asuncion FJ, Bateman TA: Soluble RANKL Induces High Bone Turnover
and Decreases Bone Volume, Density, and Strength in Mice. Calcif Tiss Int
2008, 82(5):361–372.
23. Stern A, Lauglin GA, Bergstorm J, Barret-Connor E: The sex specific
association of serum osteoprotegerin and receptor activator of nuclear
factor κB ligand with bone mineral density in older adults: The Rancho
Bernardo study. Euro Jour Endocrinol 2007, 156:555–562.
24. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentitation and
activation. Nature 2003, 423:337–342.
25. Wahab NA, Norfilza MM, Halim WNHA, Dass S: The effect of Eurycoma
longifolia jack on spermatogenesis in estrogen treated rats. Clinic 2010,
65:93–98.
26. Vanderschueren D, Jans I, Van Herck E: Time-related increase of
biochemical markers of bone turnover in androgen-deficient male rats.
Bone Miner 1994, 26:123–131.
27. Tambi MIM: Nutrients and botanical for optimizing men’s health:
Examining the evidence for Eurycoma Longifolia, the Malaysian ginseng
for men’s health. AJA 2009, 11:s5.
28. Nwe KHH, Morat PB, Khalid BAK: Opposite effects of sex steroids on
11b-hydroxysteroid dehydrogenase activity in the normal and
adrenalectomized rat testis. Gen Pharmacol 1997, 28:661–664.
29. Andras SC, Power JB, Cocking EC, Davey MR: Strategies for signal
amplification in nucleic acid detection. Mol Biotechnol 2001, 19(1):29–44.
30. Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, Ma Y, Yang W,
Crawford KL, McMaster GK, Witney F, Luo Y: A multiplex branched DNA
assay for parallel quantitative gene expression profiling. Anal Biochem
2006, 352(1):50–60.
31. Vermeulen A: Declining androgens with age - an overview. In Androgens
and the ageing male. Edited by Oddens B, Vermeulen A. New York:
Parthenon Publishing; 1996:3–14.
32. Erben RG, Erberle J, Stahr K, Goldberg M: Androgen deficiency induces
high turnover osteopenia in aged male rats: A sequential
histomorphometric study. JBMR 2000, 15(6):1085–1098.
33. Gill RK, Turner RT, Wronski TJ, Bell NH: Orcidectomy markedly reduces the
concentration of the three isomers of transforming growth factor B in
rat bone and reduction is prevented by testosterone. Endocrinol 1998,
139(2):546–550.
34. Zanoli P, Zavatti M, Montanari C, Baraldi M: Influence of Eurycoma
longifolia on the copulatory activity of sexually sluggish and impotent
male rats. Jour Ethnopharm 2009, 126(22):308–313.
Shuid et al. BMC Complementary and Alternative Medicine 2012, 12:152 Page 10 of 10
http://www.biomedcentral.com/1472-6882/12/15235. Bhat R, Karim AA: Tongkat Ali (eurycoma longifolia Jack): A review on its
ethnobotany and pharmacological importance. Fitoterapi 2010,
7(81):669–679.
36. Dalla Valle L, Belvederea P, Simontacchia C, Colombo L: Extraglandular
hormonal steroidogenesis in aged rats. J Steroid Biochem 1992,
43:1095–1098.
37. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schröder
FH: Adrenal glands of mouse and rat do not synthesize androgens. Life
Sci 1992, 50(12):857–861.
38. Zaitsu M, Yamanoi M, Mikami K, et al: Surgical Castration in Hormone-
Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for
Medical Castration. Advances in Urology 2012, doi:10.1155/2012/979154.
Article ID 979154.
39. Bartke A, Musto M, Caldwell BV, Behrman R: Effects of a cholesterol
esterase inhibitor and of prostaglandin F2α on testis cholesterol and on
plasma testosterone in mice. Prostaglandins 1973, 3:97–104.
40. Moreau MF, Libouban H, Legrand E, Baslé MF, Audran M, Chappard D: Lean
fat and bone masses are influenced by orchidectomy in the rat. A
densitometric X-ray absorptiometric study. J Musculoskel Neuron Interac
2001, 1:209–213.
41. Libouban H, Moreau MF, Legrand E: Comparison of histomorphometric
descriptors of bone architecture with dual-energy X-ray absorptiometry
for assessing bone loss in the orchidectomised rat. Osteoporos Int 2002,
13:422–428.
42. Danielsen CC, Mosekilde L, Andreassen TT: Long-term effect of
orchidectomy on cortical bone from rat femur: Bone mass and
mechanical properties. Calcif Tiss Int 1992, 50(2):169–174.
43. Díaz-Curiel M, de la Piedra C, Romero FI, Montero M, Gómez S, Lefort M,
Carrascal MT, Phipps RJ: Effect of Risedronate on Bone Mass, Remodelling
and Biomechanical Strength in Orchidectomized Rats. Horm Res 2008,
70:93–99.
44. Seeman E: Bone quality: the material and structural basis of bone
strength. J Bone Miner Metab 2008, 26:1–8.
45. Seeman E, Delmas PD: Bone quality-the material and structural basis of
bone strength and fragility. N Engl J Med 2006, 354:2250–2261.
46. Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K: Testosterone increases
osteoprotegerin expression in mouse osteoblast cells. Horm Metab Res
2004, 36(10):674–678.
47. Hofbauer LC, Heufelder AE: The role of receptor activator of NF-κB ligand
and osteoprotegerin in the pathogenesis and treatment of metabolic
bone diseases. J Clin Endocrinol Metab 2000, 85:2355–2363.
48. Proell V, Xu H, Schuler C, Weber K, Hofbauer LC, Erben RG: Orchidectomy
upregulates free soluble RANKL in bone marrow of aged rats. Bone 2009,
45:677–681.
49. Kanzaki H, Hatayama H, Narukawa S, Kariya M, Fujita J, Mori T: Hormonal
regulation in the production of macrophage colony-stimulating factor
and transforming growth factor-beta by human endometrial stromal
cells in culture. Horm Res 1995, 44(S2):30–35.
50. Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, Sambrook P:
The incidence of osteoporosis in four Asian countries: The Asian
Osteoporosis Study (AOS). Osteoporos Int 2001, 12(3):239–243.
51. Bjorgul K, Reikeras O: Incidence of hip fracture in southeastern Norway: a
study of 1,730 cervical and trochanteric fractures. Int Orthop 2007,
31(5):665–669.
doi:10.1186/1472-6882-12-152
Cite this article as: Shuid et al.: Eurycoma longifolia upregulates
osteoprotegerin gene expression in androgen- deficient osteoporosis
rat model. BMC Complementary and Alternative Medicine 2012 12:152. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
